Explore
Validate
Learn11061-2-AP
antibody from Proteintech Group
Targeting: RBMS1
C2orf12, DKFZp564H0764, HCC-4, MSSP-1, MSSP-2, MSSP-3, SCR2, YC1
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11061-2-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11061-2-AP, RRID:AB_2179121
- Product name
- RBMS1 antibody
- Antibody type
- Polyclonal
- Description
- RBMS1 antibody (Cat. #11061-2-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.
m6A methylation-modified ETV1 drives multiple myeloma progression and M2 polarization of tumor-associated macrophage through transcriptional activation of RBMS1.
RBMS1-HSPA8 axis activation drives head and neck squamous cell carcinoma progression.
Increased ANKRD1 Levels in Early Senescence Mediated by RBMS1-Elicited ANKRD1 mRNA Stabilization.
Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma.
Dai Y, Wu X, Cheng X, Shang J, Yu Z, Xia Y, Pei S, Kang Y, Jin J, Wang S, Xie H, Cui Y
Cancer letters 2026 May 28;646:218408
Cancer letters 2026 May 28;646:218408
m6A methylation-modified ETV1 drives multiple myeloma progression and M2 polarization of tumor-associated macrophage through transcriptional activation of RBMS1.
Liu Y, Geng Y, Zheng B, Zhang A, Yang K, Mao Y, Jiang L
Journal of translational medicine 2026 Feb 13;24(1)
Journal of translational medicine 2026 Feb 13;24(1)
RBMS1-HSPA8 axis activation drives head and neck squamous cell carcinoma progression.
Yin X, Luo M, Zha X, Duan M, Liu Y
BMC cancer 2025 Mar 27;25(1):549
BMC cancer 2025 Mar 27;25(1):549
Increased ANKRD1 Levels in Early Senescence Mediated by RBMS1-Elicited ANKRD1 mRNA Stabilization.
Shin CH, Rossi M, Anerillas C, Martindale JL, Yang X, Ji E, Pal A, Munk R, Yang JH, Tsitsipatis D, Mazan-Mamczarz K, Abdelmohsen K, Gorospe M
Molecular and cellular biology 2024;44(5):194-208
Molecular and cellular biology 2024;44(5):194-208
Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma.
Zhai H, Zhong S, Wu R, Mo Z, Zheng S, Xue J, Meng H, Liu M, Chen X, Zhang G, Zheng X, Du F, Li R, Zhou B
Epigenetics 2023 Dec;18(1):2192438
Epigenetics 2023 Dec;18(1):2192438
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HepG2 cells, using RBMS1 antibody 11061-2-AP at 1:100 dilution and FITC-labeled donkey anti-rabbit IgG(green). Blue pseudocolor = DAPI (fluorescent DNA dye).
- Sample type
- cell line
